Frank Knuettel II, CEO of Chromocell Therapeutics Corp., was recently a guest on Benzinga's All-Access.<br /><br />Chromocell is a clinical-stage biotech company focusing on novel pain treatments. The company's therapeutics target a specific channel in the body, NaV1.7, known for its role in pain. By blocking it, the company aims to stop pain signals from reaching the brain and spinal cord. <br /><br />Chromocell is currently specifically targeting erythromelalgia, which causes intense burning pain, redness and increased skin temperature in the feet and sometimes the hands.
